Key statistics
On Tuesday, Bicara Therapeutics Inc (BCAX:NMQ) closed at 14.97, -24.05% below its 52-week high of 19.71, set on Oct 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 15.01 |
|---|---|
| High | 15.44 |
| Low | 14.83 |
| Bid | 14.65 |
| Offer | 19.00 |
| Previous close | 14.99 |
| Average volume | 342.86k |
|---|---|
| Shares outstanding | 54.78m |
| Free float | 48.12m |
| P/E (TTM) | -- |
| Market cap | 821.18m USD |
| EPS (TTM) | -5.03 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
Announcements
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
- Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
- Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
- Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
- Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
- Bicara Therapeutics to Participate in Upcoming Investor Conferences
- Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
- Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
More ▼
